Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in most important countries of Latin America and Asia Pacific. Within I.V. generic drugs, Fresenius Kabi counts among the leading suppliers in the U.S. market. All over the world more than 24,000 employees are committed to improving the quality of life of critically and chronically ill patients with innovative products for patients in hospitals and outpatients.
We are the largest privately owned and independent plasma fractionator in the world
Family-owned since being established in 1983, Octapharma is a global healthcare company headquartered in Lachen, Switzerland. Our products are available in 118 countries and reach hundreds of thousands of patients every year. We focus on three therapeutic areas: haematology, immunotherapy and critical care.
Octapharma is one of the largest human protein product manufacturers. We develop and produce medicines based on human proteins from human cell lines and human plasma, sourced from our own plasma donation centres and other external sources.
Working at Octapharma
Octapharma focuses on long-term success and recognises the value of teamwork. We have a multicultural working environment filled with highly engaged people of diverse backgrounds and talents. Our five company values are: Ownership, Integrity, Leadership, Sustainability and Entrepreneurship. We aspire to embody these values in everything we do, every day.
The Vygon Company strategy is clear, offer health professionals efficient and innovative single-use medical products adapted to their needs. With a high degree of quality and at a competitive price, we offer health-care professionals the best possible chances to treat and care for their patients in the most secured conditions.
Innovation requires an understanding: our teams of marketing, R&D and sales representatives are working daily with our customers, listening to their needs, bringing creative and imaginative solutions to patient care. This high quality and responsive service compliments the proximity of production and research. That is why our plants are still located in Europe and in the United States of America. It’s our key to ensure constant high quality products.
This policy and strategy, requires long term commitment and a real involvement of all Vygon partners and managers. Stability and commitment of our shareholders enable us to invest in the long term, opting for quality and innovation instead of short term profitability, giving our teams and clients the warranty of a long term vision that everybody needs.
This willingness to act in the long term, some talk about Sustainable Development Strategy (SDS), allows Vygon to implement its leading vision of progress, integrating all stakeholders, in social, economic and environmental outcomes.
This strategy has proven to be effective. Since fifty years now, Vygon attracts more and more partners around the world. We are now present in more than one hundred countries in five continents. Our regular growth and profitability, warranty of our independence and our ability to innovate, testifies the quality of our products and our customer satisfaction.